1 / 22

Eugènia Negredo Fundació Lluita contra la Sida Hospital Germans Trias i Pujol Badalona

TOXICIDAD SECUNDARIA AL TRATAMIENTO ANTIRRETROVIRAL Y VIH. Eugènia Negredo Fundació Lluita contra la Sida Hospital Germans Trias i Pujol Badalona. 13 Marzo 2012. # 1130. Causas de muerte. 90 centros en Francia. N=82.000 pacientes. Cardiovascular Biomarcadores inflamatorios

marsden-cooley
Download Presentation

Eugènia Negredo Fundació Lluita contra la Sida Hospital Germans Trias i Pujol Badalona

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TOXICIDAD SECUNDARIA AL TRATAMIENTO ANTIRRETROVIRAL Y VIH Eugènia Negredo Fundació Lluita contra la Sida Hospital Germans Trias i Pujol Badalona 13 Marzo 2012

  2. # 1130. Causas de muerte 90 centros en Francia. N=82.000 pacientes

  3. Cardiovascular • Biomarcadores inflamatorios • Marcadores subclínicos • Eventos clínicos

  4. Biomarcadores de inflamación Abstracts  829-843, 1052-1057 Jason Baker #177. James Stein (cardiólogo) The value of biomarker research • VIH e inflamación: • Tamaño muestral pequeño • Observacionales • Seguimiento corto • “Inconsistent results but promising. • Treat the HIV and CVRF.”

  5. Asymmetric Dimethylarginine (ADMA) Nuevo marcador de inflamación. Marcador de disfunción arterial. Inhibidor competitivo de oxido nitroso endotelial. Consecuenciasdilatación arterial / aterosclerosis / eventos CV y muerte

  6. Asymmetric Dimethylarginine (ADMA) # 831. J Baker # 832. K Kurz # 833. R Parikh, P Shue 48sem ADMA 10,3%(p=0.003) 12sem ADMA (p<0.001) neopterina (p<0.001) VIH+  ADMA vs VIH-  CD4   ADMA  CV VIH   ADMA? VIH disfunción arterial por  ADMA (producción o eliminación?) ARV  mejora función endotelial mediada por ON a través ADMA

  7. Marcadores subclínicos Abstracts: 801-816  Ultrasonidos (cIMT)  RM (CAC)  Disfunción endotelial

  8. # 122. Microbial translocation and progression of atherosclerosis.T Kelesidis. Objective: RANKL, LPS, sCD14, dys-HDL progression of CIMT Stored samples from a prospective 3-year study (ACTG 5078) of carotid intima-media thickness (CIMT) Study population: - HIV+ (HIV RNA <500 copies/mL) n=55: - PI, n = 29; - NNRTI, n = 26 - HIV– (n = 36) matched for age, smoking status, and race.

  9. Multivariate analysis (HIV+): the yearly rate of change in cIMT - Every 10 mg/mL increase in sCD14 15.2 mm/y (95%CI 0.66 to 29.8, p = 0.04) - Every 100 pg/mL increase in LPS  0.49 mm/y (CI 0.18 to 0.81, p = 0.003). -No significant association with dys-HDL and RANKL levels

  10. # 124. Statin and Risk of Serious Non-AIDS-Defining Events (ACTG ALLRT Cohort). Edgar Overton. N= 3601 subjects who initiated ART, not on a statin at ALLRT entry. Primary endpoint: time to first major clinical event (CV event, renal or hepatic disease, incident diabetes, thrombotic or embolic event, non-traumatic fracture, non-AIDS-defining malignancy, serious bacterial infection, or non-accidental death).

  11. “Estatinas” “No-estatinas” - Reducción del 18% en el tiempo a primer evento (p=ns). - Reducción del 55% en neoplasias (aHR 0.45 (0.21 to 0.97).

  12. # 823.ATV Is Not Associated with an Increased Risk of CV Events (D:A:D). A d’Arminio Monforte 27.125 pers/año con ATV // 274.728 pers/año sin ATV

  13. METABOLISMO ÓSEO Factores predisponentes Intervención

  14. #125LB. Switching from AZT/3TC to TVD on Bone Mineral Density (Sub-study of PREPARE Study) Aoife Cotter

  15. # 878.Switch from Tenofovir to Raltegravir (TROP Study). Mark Bloch Estudio multicéntrico, no-randomizado. N= 37 pacientes con t-score <-1 SD en lumbar o femur. IP/r + TDF…  IP/r + RAL…

  16. # 886. Vitamin D Insufficiency Is Associated with HIV Disease Progression and Death.Fiona Havers

  17. TOXICIDAD RENAL Métodos diagnósticos Riñón y TDF

  18. # 862. Validation of eGFR equations compared with isotopic GFR. Eiam-Ong. 99mTc DTPA plasma clearence GFR N=196 naive; N=186 ARV eGFR infraestima el GFR Cistatina C y MDRD  metodos más aproximados.

  19. # 865. Exposure to ARV and the Risk of Renal Impairment ( D:A:D). Lene Ryom 22.603 pacientes con FGR normal en basal  2,1% progresaron a FGR<70.  0,6% a IRC (FGR<60) Pacientes con TDF, ATV i LPV progresaron más a “descenso de FGR”, como los factores riesgo tradicionales. Cambios de TDF, pero no de ATV o LPV. Monotorizar a éstos.

  20. # 870.Immune Status Plays a Key Role in Renal Recovery in Patients with Tenofovir-related Nephrotoxicity. Anna Bonjoch.

  21. Muchas gracias

More Related